Patents Examined by Bruck Kifle
  • Patent number: 10669272
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: June 2, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Upender Velaparthi, Louis S. Chupak, Chetan Padmakar Darne, Min Ding, Robert G. Gentles, Yazhong Huang, Manjunatha Narayana Rao Kamble, Scott W. Martin, Raju Mannoori, Ivar M. McDonald, Richard E. Olson, Hasibur Rahaman, Prasada Rao Jalagam, Saumya Roy, Gopikishan Tonukunuru, Sivasudar Velaiah, Jayakumar Sankara Warrier, Xiaofan Zheng, John S. Tokarski, Bireshwar Dasgupta, Kotha Rathnakar Reddy, Thiruvenkadam Raja
  • Patent number: 10669262
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: June 2, 2020
    Assignee: Incyte Corporation
    Inventors: Stacey Shepard, Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao
  • Patent number: 10669242
    Abstract: The present invention relates to benzodiazepine derivative compounds of formula (I), or pharmaceutically acceptable salts thereof. The present benzodiazepine compounds are useful Clostridium difficile inhibitors in the treatment of Clostridium difficile infection in humans. The present invention provides a pharmaceutical composition containing benzodiazepine compounds of formula (I) and a method of making as well as a method of using the same in treating patients infected with Clostridium difficile infection by administering the same. The compounds of the present invention may be used in combination with additional antibiotics or anti-toxin antibody drugs.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: June 2, 2020
    Assignee: Venenum Biodesign, LLC
    Inventors: Jeffrey J. Letourneau, Andrew G. Cole, Brett A. Marinelli, Jorge G. Quintero
  • Patent number: 10669250
    Abstract: Described herein are hypervalent iodine reagents.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: June 2, 2020
    Assignees: ETH ZURICH
    Inventors: Vaclav Matousek, Petr Beier, Antonio Togni
  • Patent number: 10669260
    Abstract: The present invention provides modulators of protein function, to restore protein homeostasis, including cytokine, aiolos, and/or ikaros activity, and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions, such as cytokine-mediated diseases, disorders, and conditions, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, and cancer, are provided.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: June 2, 2020
    Assignee: BioTheryX, Inc.
    Inventors: Kyle W. H. Chan, Leah Fung, Robert Sullivan, Paul E. Erdman, Frank Mercurio
  • Patent number: 10646577
    Abstract: Disclosed herein, inter alia, are compounds and methods of using the same for modulating the activity of mTORC1.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: May 12, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kevan Shokat, Masanori Okaniwa
  • Patent number: 10646584
    Abstract: A compound which is either A: or B: and salts and solvates thereof, as well as their conjugates with a cell-binding agent.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: May 12, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventor: Philip Wilson Howard
  • Patent number: 10633349
    Abstract: The present invention relates to a diazepine derivative represented by the following general formula (I) (in the formula, R1 and R2 represent hydrogen atom and the like, or R1 and R2 bind together to form a naphthalene ring and the like together with the benzene ring to which they bind, R3 and R4 represent hydrogen atom and the like, R5 represents hydrogen atom and the like, R6 and R7 represent hydrogen atom and the like, X represents C, CH or N, Y represents N, NH or C(?O), provided that when X is N, Y is not N or NH, and when X is C or CH, Y is not C(?O), Z represents oxygen atom or sulfur atom, A represents benzene ring and the like, B represents NHC(?O) and the like, D represents an atomic bond and the like, E represents an atomic bond and the like, G represents benzene which may be substituted and the like, and m represents an integer of 0 to 5) or a pharmacologically acceptable salt thereof, and a P2X4 receptor antagonist.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: April 28, 2020
    Assignee: NIPPON CHEMIPHAR CO., LTD
    Inventors: Masatoshi Ushioda, Kunio Kobayashi, Daisuke Saito, Shogo Sakuma, Toshiyasu Imai, Kazuhide Inoue
  • Patent number: 10633376
    Abstract: The present disclosure relates to crystalline forms of JAK1-selective inhibitor, process for preparation and use for prevention and/or treatment of diseases associated with JAK family. The crystalline forms of the present disclosure show favorable properties such as simple preparation process, good stability, low hygroscopicity and good mechanical stability.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: April 28, 2020
    Assignee: Crystal Pharmaceutical (Suzhou) Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Cunbo Yang, Kai Liu, Xiaoyu Zhang
  • Patent number: 10633362
    Abstract: This invention is a benzothiophene estrogen receptor modulator or its pharmaceutically acceptable salt or a pharmaceutically acceptable composition thereof to treat an estrogen-related medical disorder.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: April 28, 2020
    Assignee: G1 Therapeutics, Inc.
    Inventor: Jay Copeland Strum
  • Patent number: 10618912
    Abstract: The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: April 14, 2020
    Assignee: Turning Point Therapeutics, Inc.
    Inventors: Jingrong Jean Cui, Yishan Li, Evan W. Rogers, Dayong Zhai
  • Patent number: 10617706
    Abstract: The invention provides a compound of formula (I), (II) or (III): wherein R1, R2, R3, R4 and R5 have any of the values described in the specification, as well as compositions comprising a compound of formula (I), (II) or (III). The compounds and compositions are useful as chemotherapeutic sensitizing agents.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: April 14, 2020
    Assignees: REGENTS OF THE UNIVERSITY OF MINNESOTA, THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
    Inventors: Zhengqiang Wang, Jayakanth Kankanala, Yves Pommier
  • Patent number: 10611756
    Abstract: The present invention relates to methods and/or uses for treating pancreatitis, kidney diseases and other various disorders as described herein, for conditions or disorders mediated by KMO inhibitors, which comprises administering 6-chlorobenzoxazine compounds of Formula (I): or pharmaceutically acceptable salts and/or corresponding pharmaceutical compositions thereof.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: April 7, 2020
    Assignee: The University Court of The University of Edinburgh
    Inventors: Anne Marie Jeanne Bouillot, Alexis Denis, John Liddle, Olivier Mirguet, Ann Louise Walker
  • Patent number: 10604510
    Abstract: Provided herein are compositions including the crystalline forms of (1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[b]azepine-4-carboxamide (“Compound A”), methods of making the crystalline forms, and methods of using the crystalline forms for the treatment of diseases, including, for example, cancer.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: March 31, 2020
    Assignee: Celgene Corporation
    Inventors: Hon-Wah Man, Timothy D. Fitzpatrick, Anthony Frank, Ying Li, Xiaoling Lu, Marie G. Beauchamps, Antonio C. Ferretti
  • Patent number: 10604499
    Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: March 31, 2020
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Service
    Inventors: John Schneekloth, Jr., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, David Calabrese, Elena Leon
  • Patent number: 10604527
    Abstract: The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R3 are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: March 31, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Taishan Hu, Haixia Liu
  • Patent number: 10604535
    Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: March 31, 2020
    Assignee: Denali Therapeutics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Philip Leslie, Joseph P. Lyssikatos, Alfonso Pozzan, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • Patent number: 10604533
    Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: March 31, 2020
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: Koc-Kan Ho, David Diller, Jeffrey J. Letourneau, Brian F. McGuinness, Andrew G. Cole, David Rosen, Cornelis A. van Oeveren, Jason C. Pickens, Lin Zhi, Yixing Shen, Bijan Pedram
  • Patent number: 10604509
    Abstract: Provided are aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: March 31, 2020
    Assignees: GlaxoSmithKline Intellectual Property Development Limited, Astex Therapeutics Limited
    Inventors: Jeffrey K. Kerns, James Callahan, Thomas Daniel Heightman, Alison Jo-Anne Woolford, Ami Lakdawala Shah, Roderick S. Davis, David Norton, Jeffrey Charles Boehm, Nicole Cathleen Goodwin
  • Patent number: 10597406
    Abstract: The present invention provides methods for obtaining purified rapamycin derivatives, including purified Biolimus A9. A crystalline form of Biolimus A9 is also described.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: March 24, 2020
    Assignee: Biosensors International Group, Ltd.
    Inventors: Margaret W. Kayo, Richard S. Fornicola, Ivan Kovacik, Leelakrishna Kondaveti, Aniruddh Singh